We want to support your outreach efforts – across practices, within your healthcare system and at other sites. Our Health Care Provider Referral Kit gives you all the tools you need to help OnTARGET reach its enrollment goals.
Thank you for participating in this important clinical trial [NP303-102] to determine if the drug, crofelemer, is effective at preventing or reducing diarrhea in adult patients receiving targeted cancer therapy with or without chemotherapy. As targeted therapies play an ever-increasing role in cancer treatment, your work is vital to finding drugs that ensure both treatment adherence and improved patient quality of life.
Crofelemer is still investigational for this indication. It is an FDA-approved drug with an established safety profile and demonstrated efficacy for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
Importantly, you can reassure your patients that crofelemer is a safe, effective therapeutic already approved for treating diarrhea in HIV patients.
We want to support your outreach efforts – across practices, within your healthcare system and at other sites. Our Health Care Provider Referral Kit gives you all the tools you need to help OnTARGET reach its enrollment goals.
We also need your help recruiting new sites to this important study and appreciate any referrals or recommendations.
Help your patients understand the value of participating in this clinical study with our Fit to Fight educational materials.
Crofelemer is a novel antidiarrheal drug that blocks chloride ion secretion and accompanying high volume water loss in diarrhea, normalizing the flow of chloride ion and water in the gastrointestinal tract. It is orally administered and negligibly absorbed systemically. Crofelemer has no known drug-drug interactions. It is approved for treating adult patients with HIV-related non-infectious diarrhea, with efficacy and safety shown in various clinical studies when compared to placebo in the following key areas:
The most common (≤3%) side effects of crofelemer include upper respiratory infections, bronchitis, cough, flatulence, and increased bilirubin.
Learn more about the pivotal phase 3 ADVENT clinical trial in patients with HIV/AIDS.